Scott Smith, Viatris CEO
February 28, 2024 06:39 AM ESTUpdated 08:42 AM
Deals
R&D

Vi­a­tris li­cens­es Idor­sia’s PhI­II heart and lu­pus drugs with $350M up­front

Ayisha Sharma

News Reporter

Vi­a­tris has inked a deal with Idor­sia for a pair of late-stage drug can­di­dates in a move that may re­flect Vi­a­tris’ ef­forts to build its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times